BioChimPharm (BCP) is a Georgian-based biopharmaceutical company that specializes in research and development, production, and marketing of sustainable alternatives to antibiotics. Utilizing bacteriophages (phages), which are natural enemies of bacteria, the company develops innovative products to treat and prevent diseases caused by harmful bacteria. With a market share of over 85% in Georgia and exports to 10 countries, BCP is the leading provider of phage pharmaceutical products.

The company boasts unique technological expertise and over 80 years of experience in R&D and production of antibiotic alternatives. BCP is ISO 9001-2015 certified, has won multiple awards, and has a team of over 60 people, 15 registered products, and two international patents. The company's production site and R&D laboratories are located in Tbilisi, Georgia in a historic bacteriophage production facility built in 1934.

BCP operates mainly in the Human and Animal Health industries, producing therapeutic OTCs (over the counter drugs) and dietary supplements. The company's mission is to eradicate the irrational use of antibiotics and to overcome antibiotic resistance globally. With a combined effort of several generations, BioChimPharm is making revolutionary technology available worldwide. In 2021, the company invested over EUR 5 million in modernization and EU GMP compliance of its existing historical manufacturing facility of bacteriophages.

For viewing the products, please visit the link